RepublicWorld.com (India): “Akston Biosciences Launches Phase I/II Clinical Trial Of Second-Generation COVID-19 Vaccine: Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine candidate”